This podcast provides a fundamental, technical, and macroeconomic analysis of AbbVie Inc. (NYSE: ABBV), a preeminent global biopharmaceutical enterprise. The core objective of this analysis is to evaluate the operational resilience, capital allocation efficiency, and strategic positioning of the firm following the highly anticipated loss of exclusivity for its flagship immunology asset, Humira. The empirical evidence indicates that the enterprise has successfully navigated this structural transition. This success is primarily driven by the exceptional commercial trajectory of its next-generation immunology assets, Skyrizi and Rinvoq, which have already surpassed Humira’s historical peak sales.1 However, this top-line resilience is juxtaposed against profound GAAP profitability compression, a direct consequence of aggressive acquisition-related In ...